US20130303557A1 - Pharmaceutical compositions and methods of treating dry eye disorders - Google Patents

Pharmaceutical compositions and methods of treating dry eye disorders Download PDF

Info

Publication number
US20130303557A1
US20130303557A1 US13/944,816 US201313944816A US2013303557A1 US 20130303557 A1 US20130303557 A1 US 20130303557A1 US 201313944816 A US201313944816 A US 201313944816A US 2013303557 A1 US2013303557 A1 US 2013303557A1
Authority
US
United States
Prior art keywords
alkyl
dry eye
methyl
amino
tear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/944,816
Inventor
Channing Rodney BEALS
Elizabeth WoldeMussie
Hovhannes John Gukasyan
Jingwen Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US13/944,816 priority Critical patent/US20130303557A1/en
Publication of US20130303557A1 publication Critical patent/US20130303557A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Dry eye also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.
  • Dry eye may afflict an individual with varying severity. Dry eye is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
  • Aqueous tear-deficient dry eye comprises two major subclasses, Sjogren syndrome dry eye and non-Sjogren syndrome dry eye (primary and secondary lacrimal gland deficiencies, obstruction of the lacrimal gland ducts, reflex hyposecretion, reflex motor block).
  • Evaporative dry eye resulting from excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function, comprises the subclasses of intrinsic causes (meibomian gland dysfunction, lid aperture and lid/globe disorders, low blink rate) and extrinsic causes (ocular surface disorders and disease, contact lens wear, allergic conjunctivitis such as vernal keratoconjunctivitis).
  • Practitioners have taken several approaches to the treatment of dry eye.
  • One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day.
  • Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
  • Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils.
  • Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g. McCulley and Shine, Tear film structure and dry eye, Contactologio , vol. 20(4), pp 145-9 (1998).
  • Phosphilipid drug delivery systems involving phospholipids, propellants and an active substance are also known, see U.S. Pat. No. 5,174,988.
  • U.S. Pat. No. 5,041,434 discloses the use of sex steroids such as conjugated estrogens to treat dry eye conditions in post-menopausal women
  • U.S. Pat. No. 5,290,572 discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production
  • U.S. Pat. No. 4,966,773 discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
  • Jak3 inhibitors may be useful in the treatment of other inflammation-linked ocular disorders, including but not limited to glaucoma, uveitis, diabetic retinopathy and age-related macular degeneration.
  • a CNIB-funded study found that patients having the inflammatory biomarker, anticardiolipin, were four times more likely to progress in glaucoma.
  • Jak3 inhibitors have previously been suggested for the treatment of diabetes, although there appears no suggestion for diabetic retinopathy in particular. Cetkovic-Cvrle, M. and Uckun, F. M., Arch Immunol Ther Exp ( Warsz ), 52(2), 69-82 (2004).
  • Rodrigues found that the isolation of immunoglobulins, complement proteins, cytokines and activated microglia, in retinal pigment epithelium (RPE) cells and drusen provided evidence for the role of inflammation in dry age-related macular degeneration. Rodrigues E. B., Ophthalmologica, 221(3):143-52 (2007).
  • the present invention is directed to a method for the treatment of dry eye which comprises administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor.
  • the Jak3 inhibitors have the compound of formula I:
  • R 1 is a group of the formula
  • y is 0, 1 or 2;
  • R 4 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfonyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C 1 -C 4 )alkoxy, (C 1 -C 6 )acyloxy, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, cyano, nitro, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 1 -C 6 )acylamino; or R 4 is (C 3 -C 10 )cycloalkyl wherein the cycloalkyl group is optionally substituted by de
  • R 5 is (C 2 -C 9 )heterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (C 1 -C 6 )alkyl, (C r C 6 )alkoxy, halo, (C 1 -C 6 )acyl, (C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-CO—NH, (C 1 -C 6 )alkylamino-CO—, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )al
  • a is 0, 1, 2, 3 or 4; b, c, e, f and g are each independently 0 or 1; d is 0, 1, 2, or 3;
  • X is S(O) n wherein n is 0, 1 or 2; oxygen, carbonyl or —C( ⁇ N-cyano)-;
  • Y is S(O) n wherein n is 0, 1 or 2; or carbonyl; and
  • Z is carbonyl, C(O)O—, C(O)NR— or S(O) n wherein n is 0, 1 or 2;
  • R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each independently selected from the group consisting of hydrogen or (C 1 -C 6 )alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C 1 -C 6 )acyloxy, (C 1 -C 6 )acylamino, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, cyano, cyano(C 1 -C 6 )alkyl, trifluoromethyl(C 1 -C 6 )alkyl, nitro, nitro(C 1 -C 6 )alkyl or (C 1 -C 6 )acylamino;
  • R 12 is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (C 1 -C 6 )alkyl, trifluoromethyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo, (C 1 -C 6 )acyl, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-CO—NH, (C 1 -C 6 )alkylamino-CO—, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -C 6 )alkylamino, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl
  • R 2 and R 3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydroxy, nitro, carboxy, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, trifluoromethyl, trifluoromethoxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 3 -C 10 )cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substituted by one to three groups selected from halo, hydroxy, carboxy, amino(C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, (C 5 -C 9 )heteroaryl, (C 2 -C 9 )heterocycloalkyl, (C 3 -C 9 )cycloalkyl or
  • the present invention is also directed to a method for the treatment of glaucoma, uveitis, diabetic retinopathy and age-related macular degeneration comprising administering to a mammal a composition comprising a pharmaceutically effective amount of a Jak3 inhibitor having the compound of formula I.
  • the Jak3 inhibitor is 3- ⁇ (3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl ⁇ -3-oxo-propionitrile (CP0690550), which has the structure:
  • administration of the Jak3 inhibitor significantly increases tear production volume as compared to untreated tear production volume within two days. In a further aspect of the invention, administration of the Jak3 inhibitor increases tear production volume by at least 30% over initial tear production within the first two days of administration. In a further aspect, administration of the Jak3 inhibitor increases tear production volume by at least 50% over initial tear production within the first two days of administration. In a further aspect of the invention, administration of the Jak3 inhibitor increases tear production volume by at least 100% over initial tear volume within the first two days of administration. In another embodiment, the Jak3 inhibitor increases tear production volume to a level comparable to that of normal tear production. In a further aspect of this embodiment, the Jak3 inhibitor increases tear production volume to a level comparable to that of normal tear production within 8 days of initial treatment.
  • the invention comprises restoration of normal tear production in a mammal comprising administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor.
  • the JAK3 inhibitor is 3- ⁇ (3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl ⁇ -3-oxo-propionitrile (CP0690550).
  • the Jak3 inhibitor is administered at most twice a day (BID). In a further aspect, the Jak 3 inhibitor is administered daily (QD).
  • the composition is topically administered to the eye.
  • the pharmaceutically effective amount of the Jak3 inhibitor is 0.0001% to less than 1.0% (w/w). In a further aspect the amount of the Jak3 inhibitor is 0.0003% to less than 0.1% (w/w). In another aspect of the invention, the amount of the Jak3 inhibitor is 0.0003 to 0.03% (w/w). In still another aspect the amount of the Jak3 inhibitor is 0.003% to 0.005% (w/w). In still another aspect, the amount of the Jak3 inhibitor is 0.01% to 0.03% (w/w). In a still further embodiment, the amount of Jak3 inhibitor is about 0.003%, 0.005%, 0.01% or 0.03% (w/w).
  • the topical ophthalmic composition further comprises a tonicity agent and a buffer.
  • the tonicity agent is either a simple sugar or a sugar alcohol.
  • the buffer is selected from phosphate or citrate.
  • the composition further comprises a surfactant.
  • the surfactant is selected from TritonX114 and tyloxapol.
  • the composition further comprises a stabilizing polymer.
  • the stabilizing polymer is carbomer 974p.
  • FIG. 1 shows tear production of the MRL/Ipr mouse (“dry eye mouse”) versus the control C57 mouse as discussed in Example 1 below.
  • FIG. 2 shows tear production of the dry eye mouse versus the C57 mouse, as when administered with the selective Jak3 inhibitor, 3- ⁇ (3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl ⁇ -3-oxo-propionitrile (CP0690550).
  • FIG. 3 shows tear production of the Jak3 inhibitor CP0690550 as compared to the leading dry eye therapeutic Restasis®.
  • FIG. 4 shows the dose response effects of CP690550 at 0.003%, 0.01%, and 0.03% (w/w) in Formulation 1 vehicle as compared to normal and dry eye controls.
  • FIG. 5 shows the dose response effects of CP690550 at 0.001% and 0.003% (w/w) in Formulation 3 vehicle, as compared to normal and dry eye controls.
  • FIG. 6 shows the dose response effects of CP690550 at 0.001%, 0.003% and 0.01% (w/w) in Formulation 4 vehicle, as compared to normal and dry eye controls.
  • FIG. 7 shows the dose response effects of CP690550 at 0.003% and 0.01% (w/w) in Formulation 3 vehicle in an induced dry eye mouse model, as compared to normal eye and placebo vehicle controls.
  • FIG. 8 shows the dose response effects of CP690550 at 0.003% and 0.005% (w/w) in Formulation 5 vehicle in an induced dry eye mouse model, as compared to normal eye and placebo vehicle controls.
  • Jak3 Janus kinase-3
  • the Jak3 selective inhibitors of the present invention in one aspect have selectivity for inhibition of Jak3 relative to other protein tyrosine kinases, particularly the closely related family member, Jak2. This is because Jak2 controls signaling through the erythropoietin (EPO), macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage (GM)_CSF, and thrombopoietin (TPO) receptors.
  • EPO erythropoietin
  • M-CSF macrophage colony-stimulating factor
  • GM_CSF granulocyte-macrophage
  • TPO thrombopoietin
  • Jak2 deficiency is embryonically lethal due to impaired erythropoiesis. Significant pharmacologic inhibition of Jak2 in vivo could be expected to result in anemia, thrombocytopenia, and leukopenia. Pesu et al, Immunological Reviews 203, 127-142 (2005). At the enzymatic level, the Jak3 inhibitors of the present invention are at least 10 fold more potent against Jak3 versus Jak2, and are greater than 3000-fold specific relative to other kinases.
  • the present invention relates to a method of treating dry eye comprising administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor having the formula I and/or the specific embodiments as described above.
  • Jak3 inhibitors are disclosed in U.S. Pat. Nos. 6,627,754 and 7,091,208, the contents of which are incorporated by reference herein.
  • a particular embodiment of the invention comprises administering to a patient a pharmaceutically effective amount of 3- ⁇ (3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl ⁇ -3-oxo-propionitrile.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties or combinations thereof.
  • alkoxy includes O-alkyl groups wherein “alkyl” is defined above.
  • halo as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
  • the compounds of this invention may contain double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
  • alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetra
  • Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydr
  • (C 6 -C 10 )aryl when used herein refers to phenyl or naphthyl.
  • Preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 0; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 0; d is 1; e is 0; f is 0, and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 0; e is 0; f is 0; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 0; c is 0; d is 0; e is 0; f is 0; g is 1; and Z is —C(O)—O—. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; n is 2; c is 0; d is 0; e is 0; f is 0; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; n is 2; c is 0; d is 2; e is 0; f is 1; g is 1; and Z is carbonyl. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; n is 2; c is 0; d is 2; e is 0; f is 1; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 0; e is 1; Y is S(O) n ; n is 2; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; n is 2; c is 1; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 1; b is 1; X is carbonyl; c is 1; d is 0; e is 0; f is 0; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; c is 0; d is 1; e is 1; Y is S(O) n ; n is 2; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O) n ; c is 0; d is 1; e is 1; Y is S(O) n ; n is 2; f is 1; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is oxygen; c is 0; d is 1; e is 1; Y is S(O) n ; n is 2; f is 1; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is oxygen; c is 0; d is 1; e is 1; Y is S(O) n ; n is 2; f is 0; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 1; e is 1; Y is S(O) n ; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 1; e is 1; Y is S(O) n ; n is 2; f is 1; and g is 0.
  • Additional preferred compounds of formula I include those wherein R 12 is cyano, trifluoromethyl, (C 1 -C 6 )alkyl, trifluoromethyl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylamino, ((C 1 -C 6 )alkyl) 2 amino, (C 2 -C 6 )alkynyl, cyano(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-S(O) m wherein m is 0, 1 or 2.
  • compositions administered according to the present invention comprise a pharmaceutically effective amount of one or more of the specified Jak3 inhibitors.
  • a “pharmaceutically effective amount” is one which is sufficient to reduce or eliminate signs of symptoms of dry eye or other disorders requiring the wetting of the eye.
  • An effective dosage can be administered in one or more administrations.
  • an “effective amount” or “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • treatment is an approach for obtaining beneficial or desired results including clinical results.
  • beneficial or desired clinical results include, but are not limited to, reducing and/or eliminating signs of symptoms of dry eye or other disorders requiring the wetting of the eye.
  • tear production means a statistically significant (i.e. p ⁇ 0.05) increase in tear production as measured by standard ophthalmic practice, i.e. Schirmer's or phenol red threat test, fluorescein breakup time, or any of the tests described below.
  • the quantity of tears that are produced by the eye are measured: the tears are collected for approximately 5 minutes or so, to allow the ophthalmologist to determine whether the amount produced is sufficient for maintaining eye health or not. If not much tears are produced, then a tear deficient dry eye can be diagnosed. If enough tears are produced, but the patient still has symptoms of ocular discomfort, then evaporative dry eye may be diagnosed.
  • a 35 mm ⁇ 5 mm size filter paper strip is used to measure the amount of tears that are produced over a period of 5 minutes.
  • the strip is placed at the junction of the middle and lateral thirds of the lower eye lid under ambient light.
  • the patient is instructed to look forward and to blink normally during the course of the test.
  • a negative test (more than 10 mm wetting of the filter paper in 5 minutes) means that the patient produces a normal quantity of tears. Patients with dry eyes have wetting values of less than 5 mm in 5 minutes.
  • Schirmer test An important limitation of Schirmer test is that there may be considerable variability in the results of tests done at different times and by different doctors. Its main utility may really be in diagnosing patients with severe dry eyes.
  • Schirmer II test may be performed. Schirmer II test is performed by irritating the nasal mucosa with a cotton-tipped applicator prior to measuring tear production.
  • the phenol red thread test (Quick Zone®) can be used.
  • a cotton thread impregnated with phenol red dye is used.
  • Phenol red is pH sensitive and changes from yellow to red when wetted by tears.
  • the crimped end of a 70 mm long thread is placed in the lower conjunctival formix. After 15 seconds, the length of the color change on the thread—indicating the length of the thread wetted by the tears—is measured in millimeters.
  • Wetting lengths should normally be between 9 mm and 20 mm. Patients with dry eyes have wetting values of less than 9 mm.
  • FBUT Fluorescein BreakUp Time
  • Non Invasive Break up time NIRUT
  • TTT Tear Thinning Time
  • TTT mire image to distort
  • NIBUT break up
  • administration “in conjunction” includes simultaneous administration and/or administration at different times. Administration in conjunction also encompasses administration as a co-formulation or administration as separate compositions. As used herein, administration in conjunction is meant to encompass any circumstance wherein a Jak3 inhibitor and another agent are administered to an indivisual, which can occur simultaneously and/or separately. As further discussed herein, it is understood that a Jak3 inhibitor and the other agent can be administered at different dosing frequencies or intervals. For example, the Jak3 inhibitor can be administered daily, while the other agent can be administered less frequently. It is understood that the Jak3 inhibitor and the other agent can be administered using the same route of administration or different routes of administration.
  • An “individual” is a mammal, more preferably a human.
  • a “mammal” includes, but is not limited to, farm animals (such as cows), sport animals, pets (such as cats, dogs, horses), primates, mice and rats.
  • the term “restoration of normal tear production” refers to the cessation of dry eye symptoms as described in standard ophthalmic practice, such as a response score of less than 14.5 in McMonnies & Ho Dry Eye Questionnaire and/or test results (i.e. from Schirmer's, red phenol, fluorescein etc as described in Table 1) which are in the normal variable range.
  • compositions comprising one or more of the specified Jak3 inhibitors and a pharmaceutically acceptable carrier for topical ophthalmic administration or implantation into the conjunctival sac or anterior chamber of the eye is administered to a mammal in need thereof.
  • the compositions are formulated in accordance with methods known in the art for the particular route of administration desired.
  • the total amount of the Jak3 inhibitor will be about 0.0001 to less than 1.0% (w/w).
  • a preferred range of the amount of the Jak3 inhibitor is 0.0003% to less than 0.1% (w/w), while an even more preferred range of the amount of the Jak3 inhibitor is 0.003 to 0.03% (w/w).
  • Another preferred range of the amount of Jak3 inhibitor is 0.005% to 0.05% (w/w), and a still more preferred range is 0.01% to 0.03% (w/w).
  • compositions administered according to the present invention will be formulated as solutions, suspensions, emulsions and other dosage forms for topical administration.
  • Aqueous solutions are generally preferred, based on ease of formulation, as well as a patient's ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected eyes.
  • the compositions may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions. Suspensions may be preferred for Jak3 inhibitors which are sparingly soluble in water.
  • compositions administered according to the present invention may also include various other ingredients, including but not limited to tonicity agents, buffers, surfactants, stabilizing polymer, preservatives, co-solvents and viscosity building agents.
  • Preferred pharmaceutical compositions of the present invention include the inhibitor with a tonicity agent and a buffer.
  • the pharmaceutical compositions of the present invention may further optionally include a surfactant and/or a palliative agent and/or a stabilizing polymer.
  • tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions.
  • sodium chloride, potassium chloride, magnesium chloride, calcium chloride, simple sugars such as dextrose, fructose, galactose, and/or simply polyols such as the sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, and hydrogenated starch hydrolysates may be added to the composition to approximate physiological tonicity.
  • Such an amount of tonicity agent will vary, depending on the particular agent to be added.
  • compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm and most preferably at approximately 290 mOsm).
  • ophthalmically acceptable osmolality generally about 150-450 mOsm, preferably 250-350 mOsm and most preferably at approximately 290 mOsm.
  • the tonicity agents of the invention will be present in the range of 2 to 4% w/w.
  • Preferred tonicity agents of the invention include the simple sugars or the sugar alcohols.
  • a particular embodiment of the invention is D-mannitol.
  • An appropriate buffer system e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid
  • the particular concentration will vary, depending on the agent employed.
  • the buffer will be chosen to maintain a target pH within the range of pH 5 to 8, and more preferably to a target pH of pH 5 to 7.
  • Surfactants may optionally be employed to deliver higher concentrations of inhibitor.
  • the surfactants function to solubilize the inhibitor and stabilize colloid dispersion, such as micellar solution, microemulsion, emulsion and suspension.
  • Examples of surfactants which may optionally be used include polysorbate, poloxamer, polyosyl 40 stearate, polyoxyl castor oil, tyloxapol, triton, and sorbitan monolaurate.
  • Preferred surfactants to be employed in the invention have a hydrophile/lipophile/balance “HLB” in the range of 12.4 to 13.2 and are acceptable for ophthalmic use, such as TritonX114 and tyloxapol.
  • compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions.
  • aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions.
  • Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both.
  • phospholipid carrier and “artificial tears carrier” refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, “wet”, approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; (ii) are safe; and (iii) provide the appropriate delivery vehicle for the topical administration of an effective amount of one or more of the specific Jak3 inhibitors.
  • artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Visine Pure Tears®, Visine Tears Natural Tears Formula® (Johnson & Johnson) Tears Naturale®, Tears Naturale II®, Tears Naturale Free®, Bion Tears® (Alcon Laboratories, Inc. Forth Worth, Tex.), Refresh Tears®, Refresh Endura®, Refresh Plus® (Allergan Inc.).
  • phospholipid carrier formulations include those disclosed in U.S. Pat. Nos.
  • Palliative compounds designed to lubricate, “wet,” approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration of the eye are known in the art.
  • Such palliative agents may, in some cases, serve a dual function as a tonicity agent, such as the monomeric polyols (glycerol, propylene glycol, ethylene glycol).
  • the palliative compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, polymeric polyols, such as polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxyl propylcellulose (“HPC”), dextrans, such as dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as polyvinyl alcohol, polyvinylpyrrolidinone, povidone, and carbomers, such as, carbomer 941, carbomer 940, carbomer 971P, carbomer 974P.
  • monomeric polyols such as polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxyl propylcellulose (“HPC”), dextrans, such as dextran 70
  • water soluble proteins such as gelatin
  • vinyl polymers such as polyvinyl alcohol, polyvinylpyrrolidinone, povidone
  • Additional agents that may be added to the ophthalmic compositions of the present invention are demulcents which function as a stabilizing polymer.
  • the stabilizing polymer should be an ionic/charged example with precedence for topical ocular use, more specifically a polymer that carries negative charge on it's surface that can exhibit a zeta-potential of ( ⁇ )10-50 mV for physical stability and capable of making a dispersion in water (i.e. water soluble).
  • a preferred stabilizing polymer of the invention would be polyelectrolyte or polyectrolytes if more than one, from the family of cross-linked polyacrylates, such as carbomers and Pemulen®, specifically Carbomer 974p (polyacrylic acid), at 0.1-0.5% w/w. As noted above, the carbomers may also function as a palliative compound.
  • viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers.
  • the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises (“cps”).
  • Topical ophthalmic products are typically packaged in multidose form. Preservative are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edentate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
  • compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye.
  • such compositions will be administered topically.
  • the doses used for the above described purposes will bary but will be in an effective amount to eliminate or improve dry eye conditions.
  • 1-2 drops of such compositions will be administered from once to many times per day.
  • such compositions will be administered once (QD) or twice (BID) daily.
  • Example 2 Representative eye drop formulations are provided in Example 2 below.
  • Triacetoxy sodium borohydride (4.9 grams, 23 mmol) was added and the new mixture stirred at room temperature in a sealed tube for 24 h, at which time, the reaction was quenched upon addition of 1 N sodium hydroxide (50 mL). The reaction mixture was then extracted 3 ⁇ 80 mL with ether, the combined ether layers dried over sodium sulfate (Na 2 SO 4 ) and concentrated to dryness in vacuo affording 1.7 grams (69%) of the title compound as a white solid. LRMS: 219.1 (M+1).
  • the citrate salt was prepared using methods described in WO2007/012953.
  • methyl-4(-methyl-piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine (25.0 g, 0.102 mol) and methylene chloride (250 ml).
  • the mixture was stirred at room temperature for a minimum of 2.5 hours.
  • nitrogen-purged 1 L reactor were charged cyanoacetic acid (18.2 g, 0.214 mol), methylene chloride (375 ml), and triethyl amine (30.1 ml, 0.214 mol). The mixture was cooled to ⁇ 15-5.0° C.
  • a solution of citric acid (20.76 g, 0.107 mol) in water (25.0) was charged and the mixture was cooled to room temperature.
  • the reactor was stirred for a minimum of 5 hours and then the resulting solids were isolated by filtration and washed with acetone (2 ⁇ 75 ml), which was sent to the filter.
  • the salt was charged into a clean, dry, nitrogen-purged 1 L reactor with 2B ethanol (190 ml) and water (190 ml).
  • the slurry was heated to 75-85° C. for a minimum of 4 hours.
  • the mixture was cooled to 20-30° C. and stirred for an additional 4 hours.
  • the solids were isolated by filtration and washed with 2B ethanol (190 ml). After drying in a vacuum oven at 50° C. with a slight nitrogen bleed, 34.6 g (67.3%) of the title compound were isolated.
  • Table 2 illustrates various pharmaceutical formulations comprising the inhibitor CP0690550.
  • Formulation 1 50 mM pH 7.4 phosphate buffer, 0.05% Tween 80, 0.5% NaCl Formulation 2 50 mM pH 7.4 Phosphate buffer, 0.36% HPMC, 0.2% Glycerin, 1% PEG400, 0.35% NaCl Formulation 3 5 mM pH 7.4 phosphate buffer, 0.36% HPMC, 0.2% Glyerin, 1% PEG400, 5% Cremophor ELP, 4.3% Mannitol Formulation 4 10 mM pH 5.8 citrate buffer, 4.5% Mannitol Formulation 5 10 mM pH 5.8 citrate buffer, 4.2% Mannitol, 0.36% HPMC, 0.2% Glycerin Formulation 6 0.3% tyloxapol (surfactant, nonionic), 0.5% Carbopol974P (polymeric stabilizer, anionic), 2.25% D-mannitol, pH 6.5 phosphate buffer at 50 mM concentration, 230 mOsm/kg Formulation 7
  • Each of the above formulations 1 through 5 were prepared comprising the Jak3 inhibitor CP0690550 in three dosage amounts: 0.001%, 0.003% and 0.01% w/w.
  • Formulation 5 was also prepared with the Jak3 inhibitor CP9690550 in the amount of 0.005% w/w (see FIG. 8 ).
  • Formulations 6 and 7 were prepared comprising Jak3 inhibitor in the amount of 0.03% w/w.
  • the above formulations were prepared by adding the required amount of the tonicity agent (hypromellose, or mannitol where present) to a flask, heating to about to about 50° C. in half the final volume of buffer (phosphate or citrate buffer as indicated). After heating the batch quantities of inhibitor CP690550, the additional excipients (glycerin, polyethylene glycol 400, where indicated) were weighed and dissolved. The batch quantity of the Jak3 inhibitor free base as a stock solution was measured and added. Purified water was added to q.s. to 100%. The mixture was stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane into a sterile recipient. If necessary, pH was adjusted by admixture of 1.0 NaOH.
  • the tonicity agent hypermethylcellulose, or mannitol where present
  • Formulations 6 and 7 represent ophthalmic compositions in which higher amounts of the inhibitor CP690550 are present (0.03% w/w).
  • a surfactant and optionally a stabilizing polymer.
  • Preferred surfactants of the invention include TritonX114 and tyloxapol.
  • Preferred stabilizing polymers include the carbomer 974p.
  • Formulations 6 and 7 were prepared by dispersing the carbomer first in the surfactant containing buffer at 10 ⁇ of their final concentration (e.g. 3% tyloxapol in 50 mM phosphate buffer at pH6.5 with 2.5% D-manitol and 5% Carbomer 974p).
  • the Jak3 inhibitor CP690550 was dispersed in the preconcentrate also at 10 ⁇ of its final concentration. The mixture was then homogenized, with final formulation being obtained by 10 ⁇ dilution of filtered preconcentrate in a matching buffer.
  • mice 10 MRL/Ipr mice and 5 of the age-matched C57 Black/6 control mice at 8 weeks of age were purchased from Jackson Laboratory (Bar Harbor, Me., USA).
  • the mouse strain MRL/Ipr has a mutation which predisposes it to dry eye similar to Sjogren's Syndrome.
  • mice Animals (5-10 mice/group) were treated with 2 ⁇ l of either vehicle (phosphate buffered saline, PBS, containing 0.05% Tween 80) or 0.1% (w/w) CP-690550 twice a day for two weeks. C57 mice also received vehicle. Tear volume was measured on days 2, 3, and 6. The effect of CP-690550 on tear production in MRL/Ipr Mice is shown in FIG. 2 .
  • vehicle phosphate buffered saline, PBS, containing 0.05% Tween 80
  • CP-690550 0.1%
  • CP0690550 was able to significantly increase tear production volume within the first 2 days of application.
  • CP690550 increased tear production volume by over 100% over initial tear production of the dry eye mice within the first 2 days of application.
  • Tear measurement was done using phenol red impregnated thread (Quick Zone®) and baseline measurement was performed before each drug application. Drugs or vehicles were applied at 2 ⁇ l, two times a day.
  • Vehicle-treated normal C57black/6 and MRL/Ipr dry eye mice were used as normal control and dry eye control, respectively.
  • the vehicle for CP690550 was phosphate buffered saline, PBS, containing 0.05% Tween 80.
  • CP690550 had a much faster response rate as compared to Restasis® and showed a significant improvement in the volume of tear production over Restasis®
  • both FIGS. 3 and 4 indicate that administration of CP690550 ultimately increased tear production volume to a level comparable to that of normal tear production (within 5 to 10% of tear production by “normal” C57mice).
  • Example 4 vehicle-treated normal C57black/6 and MRL/Ipr dry eye mice (5-10 mice/group) were used as normal control and dry eye control, respectively.
  • the vehicles for CP690550 were Formulations 1, 3 and 4 as indicated in Example 2 above.
  • the Jak3 inhibitor CP690550 was applied at 0.003% (w/w), 01% (w/w) and 0.03% (w/w), as calculated for free base concentration.
  • Treatment for Formulation 1 was carried for two weeks, at 41, twice a day.
  • Treatment for Formulations 3 and 4 were carried for 2 weeks, at 1 ⁇ l, once a day.
  • FIG. 4 illustrates that within 8 days, administration of CP690550 in Formulation 1 vehicle at 0.01% (w/w) twice a day increased tear production to a level comparable to that of normal tear production (within 5 to 10% of tear production by C57 normal mice).
  • FIGS. 5 and 6 illustrate dose response rates of CP690550 in Formulations 3 and 4 vehicle. In all comparisons, significant improvement in tear production was shown at 2 days after treatment.
  • An injection was prepared comprising 2.5 mg/ml scopolamine (sigma) in injectable saline (1-1.5 ml per animal).
  • scopolamine sigma
  • injectable saline 1-1.5 ml per animal.
  • mice normal C57 mice (200-250)
  • ul of scopolamine was injected four times every 2.5 hrs in alternating hind quarters.
  • the mice were placed in special cages (with holes in front and back) and placed in a hood. Fans were placed in front of each cage, and turned on for 16 hours over night for five days. Measurements were taken daily. At the end of 5 days, all animals were considered dry-induced.
  • FIGS. 7 and 8 illustrate that a significant increase in tear production was shown at 2 days of treatment. After 4 days of treatment, formulations comprising 0.01% (w/w) of CP0690550 inhibitor in Formulation 3 and 0.003% of CP690550 inhibitor in Formulation 5 approximated normal tear production values.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ophthalmic compositions comprising Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Description

  • This application is a divisional of U.S. application Ser. No. 12/688,604, which is a National Stage Application under 35 U.S.C. §371 of PCT/IB2008/001819, filed on Jul. 4, 2008, which claims the benefit of U.S. Provisional Application No. 60/949,216, filed on Jul. 11, 2007 and U.S. Provisional Application No. 61/060,032, filed on Jun. 9, 2008, the entire contents of which are incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.
  • Dry eye may afflict an individual with varying severity. Dry eye is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
  • The etiopathogenic classification of dry eye was first developed in 1995 by the National Eye Institute/Industry Dry Eye Workshop and was further updated in the January 2007 definition. The Ocular Surface, vol. 5, no. 2, 75-92 (2007). The major classes of dry eye include aqueous tear-deficient dry eye and evaporative dry eye. Aqueous tear-deficient dry eye comprises two major subclasses, Sjogren syndrome dry eye and non-Sjogren syndrome dry eye (primary and secondary lacrimal gland deficiencies, obstruction of the lacrimal gland ducts, reflex hyposecretion, reflex motor block). Evaporative dry eye, resulting from excessive water loss from the exposed ocular surface in the presence of normal lacrimal secretory function, comprises the subclasses of intrinsic causes (meibomian gland dysfunction, lid aperture and lid/globe disorders, low blink rate) and extrinsic causes (ocular surface disorders and disease, contact lens wear, allergic conjunctivitis such as vernal keratoconjunctivitis).
  • Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface and many of the symptoms outlined above (Lemp, Report of the national Eye Institute/Industry workshop on Clinical Trials in Dry Eyes, the CLAO Journal, vol. 21, no. 4, pp 221-231 (1995).
  • Practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
  • Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g. McCulley and Shine, Tear film structure and dry eye, Contactologio, vol. 20(4), pp 145-9 (1998). Phosphilipid drug delivery systems involving phospholipids, propellants and an active substance are also known, see U.S. Pat. No. 5,174,988.
  • Another approach involves the provision of lubricating substances in lieu of artificial tears. For example, U.S. Pat. No. 4,818,537 (Guo) discloses the use of a lubricating liposome-based composition, and U.S. Pat. No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
  • Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive. Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
  • Aside from efforts directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, U.S. Pat. No. 5,041,434 (Lubkin) discloses the use of sex steroids such as conjugated estrogens to treat dry eye conditions in post-menopausal women; U.S. Pat. No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and U.S. Pat. No. 4,966,773 (Gressel et al.) discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
  • Some literature reports suggest that patients suffering from dry eye syndrome disproportionately exhibit the hallmarks of excessive inflammation in relevant ocular tissues, such as the lacrimal and meibomian glands. The use of various compounds to treat dry eye patients, such as steroids e.g. U.S. Pat. No. 5,968,912; Marsh, et al., Topical nonpreserved methylprednisolone therapty for keratoconjunctivitis sicca in Sjogren syndrome, Ophthalmology, 106(5): 881-816 (1999); Plugfelder et al, U.S. Pat. No. 6,153,607]; cytokine release inhibitors (Yanni, J. M.; et al WO0003705 A1), cyclosporine A [Tauber, J. Adv. Exp. Med. Biol. 1998, 438, (Lacrimal Gland, Tear From and Dry Eye Syndromes 2), 969] and 15-HETE (Yanni et al., U.S. Pat. No. 5,696,166) has been disclosed.
  • In addition to dry eye, Jak3 inhibitors may be useful in the treatment of other inflammation-linked ocular disorders, including but not limited to glaucoma, uveitis, diabetic retinopathy and age-related macular degeneration. A CNIB-funded study found that patients having the inflammatory biomarker, anticardiolipin, were four times more likely to progress in glaucoma. Jak3 inhibitors have previously been suggested for the treatment of diabetes, although there appears no suggestion for diabetic retinopathy in particular. Cetkovic-Cvrle, M. and Uckun, F. M., Arch Immunol Ther Exp (Warsz), 52(2), 69-82 (2004). Rodrigues found that the isolation of immunoglobulins, complement proteins, cytokines and activated microglia, in retinal pigment epithelium (RPE) cells and drusen provided evidence for the role of inflammation in dry age-related macular degeneration. Rodrigues E. B., Ophthalmologica, 221(3):143-52 (2007).
    • SUMMARY OF THE INVENTION
  • The present invention is directed to a method for the treatment of dry eye which comprises administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor. In one aspect, the Jak3 inhibitors have the compound of formula I:
  • Figure US20130303557A1-20131114-C00001
  • wherein
  • R1 is a group of the formula
  • Figure US20130303557A1-20131114-C00002
  • wherein y is 0, 1 or 2;
  • R4 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C2-C6)alkenyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C4)alkoxy, (C1-C6)acyloxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, nitro, (C2-C6)alkenyl, (C2-C6)alkynyl or (C1-C6)acylamino; or R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
  • R5 is (C2-C9)heterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (C1-C6)alkyl, (Cr C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, (C1-C6)alkyl-S(O)m, R15R16NS(O)m, R15R16NS(O)m (C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl; or a group of the formula
  • Figure US20130303557A1-20131114-C00003
  • wherein a is 0, 1, 2, 3 or 4;
    b, c, e, f and g are each independently 0 or 1;
    d is 0, 1, 2, or 3;
    X is S(O)n wherein n is 0, 1 or 2; oxygen, carbonyl or —C(═N-cyano)-;
    Y is S(O)n wherein n is 0, 1 or 2; or carbonyl; and
    Z is carbonyl, C(O)O—, C(O)NR— or S(O)n wherein n is 0, 1 or 2;
  • R6, R7, R8, R9, R10 and R11 are each independently selected from the group consisting of hydrogen or (C1-C6)alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
  • R12 is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, ((C1-C6)alkyl)2 amino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylamino, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, R15C(O)NH, R15OC(O)NH, R15NHC(O)NH, (C1-C6)alkyl-S(O)m, (C1-C6)alkyl-S(O)m—(C1-C6)alkyl, R15R16NS(O)m, R15R16NS(O)m (C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl;
  • R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydroxy, nitro, carboxy, (C2-C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substituted by one to three groups selected from halo, hydroxy, carboxy, amino(C1-C6)alkylthio, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C3-C9)cycloalkyl or (C6-C10)aryl; or R2 and R3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C1-C6)alkylthio, (C6-C10)arylthio, (C1-C6)alkylsulfinyl, (C6-C10)arylsulfinyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)acyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyamino-CO—, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl or (C6-C10)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C1-C6)alkyl, (C1-C6)alkyl-CO—NH—, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, carboxy(C1-C6)alkoxy, benzyloxycarbonyl(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl(C1-C6)alkoxy, (C6-C10)aryl, amino, amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino, (C6-C10)aryl(C1-C6)alkoxycarbonylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—, cyano, (C5-C9)heterocycloalkyl, amino-CO—NH—, (C1-C6)alkylamino-CO—NH—, ((C1-C6)alkyl)2amino-CO—NH—, (C6-C10)arylamino-CO—NH—, (C5-C9)heteroarylamino-CO—NH—, (C1-C6)alkylamino-CO—NH—(C1-C6)alkyl, ((C1-C6)alkyl)2 amino-CO—NH—(C1-C6)alkyl, (C6-C10)arylamino-CO—NH—(C1-C6)alkyl, (C5-C9)heteroarylamino-CO—NH—(C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C6-C10)arylsulfonyl, (C6-C10)arylsulfonylamino, (C6-C10)arylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C5-C9)heteroaryl or (C2-C9)heterocycloalkyl, or the pharmaceutically acceptable salts thereof.
  • The present invention is also directed to a method for the treatment of glaucoma, uveitis, diabetic retinopathy and age-related macular degeneration comprising administering to a mammal a composition comprising a pharmaceutically effective amount of a Jak3 inhibitor having the compound of formula I.
  • Specific compounds of formula I include those wherein said compound is selected from the group consisting of:
    • Methyl-[4-methyl-1-(propane-1-sulfonyl)-piperidin-3-yl]-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
    • 4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid methyl ester;
    • 3,3,3-Trifluoro-1-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
    • 4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxylic acid dimethylamide;
    • ({4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carbonyl}-amino)-acetic acid ethyl ester;
    • 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile;
    • 3,3,3-Trifluoro-1-{4-methyl-3-[methyl-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-propan-1-one;
    • 1-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-but-3-yn-1-one;
    • 1-{3-[(5-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4-methyl-piperidin-1-yl}-propan-1-one;
    • 1-{3-[(5-Fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amino]-4-methyl-piperidin-1-yl}-propan-1-one;
    • N-cyano-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-N′-propyl-piperidine-1-carboxamidine; and
    • N-cyano-4,N′,N′-Trimethyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidine-1-carboxamidine.
  • In a particular embodiment, the Jak3 inhibitor is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550), which has the structure:
  • Figure US20130303557A1-20131114-C00004
  • In one aspect of the invention, administration of the Jak3 inhibitor significantly increases tear production volume as compared to untreated tear production volume within two days. In a further aspect of the invention, administration of the Jak3 inhibitor increases tear production volume by at least 30% over initial tear production within the first two days of administration. In a further aspect, administration of the Jak3 inhibitor increases tear production volume by at least 50% over initial tear production within the first two days of administration. In a further aspect of the invention, administration of the Jak3 inhibitor increases tear production volume by at least 100% over initial tear volume within the first two days of administration. In another embodiment, the Jak3 inhibitor increases tear production volume to a level comparable to that of normal tear production. In a further aspect of this embodiment, the Jak3 inhibitor increases tear production volume to a level comparable to that of normal tear production within 8 days of initial treatment.
  • In an alternative embodiment, the invention comprises restoration of normal tear production in a mammal comprising administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor. In one aspect of this embodiment, the JAK3 inhibitor is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550).
  • In another aspect of the invention, the Jak3 inhibitor is administered at most twice a day (BID). In a further aspect, the Jak 3 inhibitor is administered daily (QD).
  • In a further aspect of the invention, the composition is topically administered to the eye.
  • In another aspect of the invention, the pharmaceutically effective amount of the Jak3 inhibitor is 0.0001% to less than 1.0% (w/w). In a further aspect the amount of the Jak3 inhibitor is 0.0003% to less than 0.1% (w/w). In another aspect of the invention, the amount of the Jak3 inhibitor is 0.0003 to 0.03% (w/w). In still another aspect the amount of the Jak3 inhibitor is 0.003% to 0.005% (w/w). In still another aspect, the amount of the Jak3 inhibitor is 0.01% to 0.03% (w/w). In a still further embodiment, the amount of Jak3 inhibitor is about 0.003%, 0.005%, 0.01% or 0.03% (w/w).
  • In another aspect of the invention, the topical ophthalmic composition further comprises a tonicity agent and a buffer. In a still another aspect of the invention, the tonicity agent is either a simple sugar or a sugar alcohol. In still another aspect of the invention, the buffer is selected from phosphate or citrate.
  • In still another aspect of the invention, the composition further comprises a surfactant. In a preferred embodiment of the invention, the surfactant is selected from TritonX114 and tyloxapol. In further aspect of this embodiment, the composition further comprises a stabilizing polymer. In a still further aspect of the invention, the stabilizing polymer is carbomer 974p.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows tear production of the MRL/Ipr mouse (“dry eye mouse”) versus the control C57 mouse as discussed in Example 1 below.
  • FIG. 2 shows tear production of the dry eye mouse versus the C57 mouse, as when administered with the selective Jak3 inhibitor, 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550).
  • FIG. 3 shows tear production of the Jak3 inhibitor CP0690550 as compared to the leading dry eye therapeutic Restasis®.
  • FIG. 4 shows the dose response effects of CP690550 at 0.003%, 0.01%, and 0.03% (w/w) in Formulation 1 vehicle as compared to normal and dry eye controls.
  • FIG. 5 shows the dose response effects of CP690550 at 0.001% and 0.003% (w/w) in Formulation 3 vehicle, as compared to normal and dry eye controls.
  • FIG. 6 shows the dose response effects of CP690550 at 0.001%, 0.003% and 0.01% (w/w) in Formulation 4 vehicle, as compared to normal and dry eye controls.
  • FIG. 7 shows the dose response effects of CP690550 at 0.003% and 0.01% (w/w) in Formulation 3 vehicle in an induced dry eye mouse model, as compared to normal eye and placebo vehicle controls.
  • FIG. 8 shows the dose response effects of CP690550 at 0.003% and 0.005% (w/w) in Formulation 5 vehicle in an induced dry eye mouse model, as compared to normal eye and placebo vehicle controls.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • According to the present invention, inhibitors of Janus kinase-3 (Jak3), are administered to a mammal suffering from dry eye, and in particular, to a human patient suffering from dry eye. The Jak3 selective inhibitors of the present invention in one aspect have selectivity for inhibition of Jak3 relative to other protein tyrosine kinases, particularly the closely related family member, Jak2. This is because Jak2 controls signaling through the erythropoietin (EPO), macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage (GM)_CSF, and thrombopoietin (TPO) receptors. Moreover Jak2 deficiency is embryonically lethal due to impaired erythropoiesis. Significant pharmacologic inhibition of Jak2 in vivo could be expected to result in anemia, thrombocytopenia, and leukopenia. Pesu et al, Immunological Reviews 203, 127-142 (2005). At the enzymatic level, the Jak3 inhibitors of the present invention are at least 10 fold more potent against Jak3 versus Jak2, and are greater than 3000-fold specific relative to other kinases.
  • The present invention relates to a method of treating dry eye comprising administering to a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a Janus kinase-3 (“Jak3”) inhibitor having the formula I and/or the specific embodiments as described above. Jak3 inhibitors are disclosed in U.S. Pat. Nos. 6,627,754 and 7,091,208, the contents of which are incorporated by reference herein. A particular embodiment of the invention comprises administering to a patient a pharmaceutically effective amount of 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile.
  • The term “alkyl”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties or combinations thereof.
  • The term “alkoxy”, as used herein, includes O-alkyl groups wherein “alkyl” is defined above.
  • The term “halo”, as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo.
  • The compounds of this invention may contain double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.
  • Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.
  • (C2-C9)Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, chromanyl, etc. One of ordinary skill in the art will understand that the connection of said (C2-C9)heterocycloalkyl rings is through a carbon or a sp3 hybridized nitrogen heteroatom.
  • (C2-C9)Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5,6,7,8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc. One of ordinary skill in the art will understand that the connection of said (C2-C9)heterocycloalkyl rings is through a carbon atom or a sp3 hybridized nitrogen heteroatom.
  • (C6-C10)aryl when used herein refers to phenyl or naphthyl.
  • Preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 0; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 0; d is 1; e is 0; f is 0, and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is —C(═N=cyano)-; c is 1; d is 0; e is 0; f is 0; and g is 0.
  • Additional preferred compounds of formula I include those wherein a is 0; b is 0; c is 0; d is 0; e is 0; f is 0; g is 1; and Z is —C(O)—O—. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; n is 2; c is 0; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; n is 2; c is 0; d is 2; e is 0; f is 1; g is 1; and Z is carbonyl. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; n is 2; c is 0; d is 2; e is 0; f is 1; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 0; e is 1; Y is S(O)n; n is 2; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; n is 2; c is 1; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 1; b is 1; X is carbonyl; c is 1; d is 0; e is 0; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; c is 0; d is 1; e is 1; Y is S(O)n; n is 2; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is S(O)n; c is 0; d is 1; e is 1; Y is S(O)n; n is 2; f is 1; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is oxygen; c is 0; d is 1; e is 1; Y is S(O)n; n is 2; f is 1; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is oxygen; c is 0; d is 1; e is 1; Y is S(O)n; n is 2; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 1; e is 1; Y is S(O)n; f is 0; and g is 0. Additional preferred compounds of formula I include those wherein a is 0; b is 1; X is carbonyl; c is 1; d is 1; e is 1; Y is S(O)n; n is 2; f is 1; and g is 0. Additional preferred compounds of formula I include those wherein R12 is cyano, trifluoromethyl, (C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C2-C6)alkynyl, cyano(C1-C6)alkyl, (C1-C6)alkyl-S(O)m wherein m is 0, 1 or 2.
  • The compositions administered according to the present invention comprise a pharmaceutically effective amount of one or more of the specified Jak3 inhibitors. As used herein, a “pharmaceutically effective amount” is one which is sufficient to reduce or eliminate signs of symptoms of dry eye or other disorders requiring the wetting of the eye. An effective dosage can be administered in one or more administrations.
  • As is understood in the clinical context, administration of an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective amount” or “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, reducing and/or eliminating signs of symptoms of dry eye or other disorders requiring the wetting of the eye.
  • Most clinicians diagnose and treat Dry Eye Syndrome based on the symptoms alone (JAMA 2001; 286:2114-9). Responses to the McMonnies & Ho Dry Eye Questionnaire can be used as a tool to assess the symptoms of dry eye (score of more than 14.5 is consistent with dry eye diagnosis). Nonetheless, the National Eye Institute workshop on dry eyes defines ‘symptoms of ocular discomfort’ as only one aspect of ‘dry eyes’. An analysis of demonstrable tear deficiency or possibility of excessive tear evaporation and damage to the exposed surface of the eye, can provide confirmation of a ‘dry eye’ diagnosis.
  • As used herein, “significantly increases tear production” means a statistically significant (i.e. p<0.05) increase in tear production as measured by standard ophthalmic practice, i.e. Schirmer's or phenol red threat test, fluorescein breakup time, or any of the tests described below.
  • The most common tests for dry eye are tear film break-up time, Schirmer test and fluorescein staining, although these tests are non-exhaustive. The following are known tests for dry eye and the cutoff value at which they are considered abnormal and indicative of dry eyes:
  • TABLE 1
    TEST Abnormal cutoff value for dry eye diagnosis
    Schirmer's I Less than or equal to 5 mm wetting over 5 min
    Phenol Red Thread Less than 9 mm
    Tear Breakup time Less than or equal to 10 seconds
    Fluorescein staining More than 3 out of 15
    Rose Bengal staining More than 3 out of 18
    Tear film osmolarity Less than or equal to 312 mOsm/L
    Impression cytology More than 1
    Brush cytology More than 1
    Tear lactoferrin Less than or equal to 0.9 ug/mL
    • Schirmer's I Test
  • In the Schirmer I test, the quantity of tears that are produced by the eye are measured: the tears are collected for approximately 5 minutes or so, to allow the ophthalmologist to determine whether the amount produced is sufficient for maintaining eye health or not. If not much tears are produced, then a tear deficient dry eye can be diagnosed. If enough tears are produced, but the patient still has symptoms of ocular discomfort, then evaporative dry eye may be diagnosed.
  • In the Schirmer I test, a 35 mm×5 mm size filter paper strip is used to measure the amount of tears that are produced over a period of 5 minutes. The strip is placed at the junction of the middle and lateral thirds of the lower eye lid under ambient light. The patient is instructed to look forward and to blink normally during the course of the test. A negative test (more than 10 mm wetting of the filter paper in 5 minutes) means that the patient produces a normal quantity of tears. Patients with dry eyes have wetting values of less than 5 mm in 5 minutes.
  • An important limitation of Schirmer test is that there may be considerable variability in the results of tests done at different times and by different doctors. Its main utility may really be in diagnosing patients with severe dry eyes.
  • There is some debate about the Schirmer I test. When an anesthetic eyedrop is NOT used then this test is thought to measure basal and reflex tear secretion. When an anesthetic eyedrop IS used then this test is thought to measure only the basic tear secretion. There is compelling reason to believe that the tears measured by these two different methods may not sufficiently differentiate between basic and reflex tear production. Most clinicians perform this test after using anesthetic eyedrops to numb the eye. However, The National Eye Institute workshop on dry eyes recommended not to use anesthetic eyedrops before performing this test. The cutoff value is similar whether or not anesthetic is used. To measure the reflex tear secretion Schirmer II test may be performed. Schirmer II test is performed by irritating the nasal mucosa with a cotton-tipped applicator prior to measuring tear production.
  • As an alternative to the Schirmer I or II test, which some clinicians consider unduly invasive and of little value for mild to moderate dry eyes, the phenol red thread test (Quick Zone®) can be used. A cotton thread impregnated with phenol red dye is used. Phenol red is pH sensitive and changes from yellow to red when wetted by tears. The crimped end of a 70 mm long thread is placed in the lower conjunctival formix. After 15 seconds, the length of the color change on the thread—indicating the length of the thread wetted by the tears—is measured in millimeters. Wetting lengths should normally be between 9 mm and 20 mm. Patients with dry eyes have wetting values of less than 9 mm.
    • Tear Breakup Time (BUT)
  • In patients with dry eyes the tear film is unstable, and breaks up faster. Therefore the tear break up time in patients who have dry eyes is shorter. Fluorescein BreakUp Time (FBUT) is used most commonly. A strip of fluorescein is applied in the lower eyelid formix and then removed. The patient is asked to blink three times and then look straight forward, without blinking. The tear film is observed under cobalt-blue filtered light of the slitlamp microscope and the time that elapsed between the last blink and appearance of the first break in the tear film is recorded with a stopwatch (a break is seen as a dark spot in a sea of blue). Fluorescein BUT of less than 10 seconds or less is consistent with dry eyes.
  • To overcome limitations caused by the potential invasiveness of the FBUT test, Non Invasive Break up time (NIBUT) methods have been developed. They are called Non Invasive because the eye is not touched. Instruments such as a keratometer, hand-held keratoscope or Tearscope are required to measure NIBUT. A prerupture phase that precedes actual break up of the tear film can also be observed with some techniques. This pre-rupture phase is termed Tear Thinning Time (TTT). Measurement is achieved by observing the distortion (TTT) and/or break up (NIBUT) of a keratometer mire (the reflected image of keratometer grid). The clinician focuses and views the crisp mires, and then records the time taken for the mire image to distort (TTT) and/or break up (NIBUT). NIBUT measurements are longer than fluorescein break up time. NIBUT values of less than 15 seconds are consistent with dry eyes. TTT/NIBUT are considered to be more patient-friendly, repeatable and precise.
  • As used herein, administration “in conjunction” includes simultaneous administration and/or administration at different times. Administration in conjunction also encompasses administration as a co-formulation or administration as separate compositions. As used herein, administration in conjunction is meant to encompass any circumstance wherein a Jak3 inhibitor and another agent are administered to an indivisual, which can occur simultaneously and/or separately. As further discussed herein, it is understood that a Jak3 inhibitor and the other agent can be administered at different dosing frequencies or intervals. For example, the Jak3 inhibitor can be administered daily, while the other agent can be administered less frequently. It is understood that the Jak3 inhibitor and the other agent can be administered using the same route of administration or different routes of administration.
  • An “individual” (alternatively referred to as a “subject”) is a mammal, more preferably a human. A “mammal” includes, but is not limited to, farm animals (such as cows), sport animals, pets (such as cats, dogs, horses), primates, mice and rats.
  • The term “restoration of normal tear production” refers to the cessation of dry eye symptoms as described in standard ophthalmic practice, such as a response score of less than 14.5 in McMonnies & Ho Dry Eye Questionnaire and/or test results (i.e. from Schirmer's, red phenol, fluorescein etc as described in Table 1) which are in the normal variable range.
  • According to the methods of the present invention, a composition comprising one or more of the specified Jak3 inhibitors and a pharmaceutically acceptable carrier for topical ophthalmic administration or implantation into the conjunctival sac or anterior chamber of the eye is administered to a mammal in need thereof. The compositions are formulated in accordance with methods known in the art for the particular route of administration desired.
  • Generally, for compositions intended to be administered topically to the eye in the form of eye drops or eye ointments, the total amount of the Jak3 inhibitor will be about 0.0001 to less than 1.0% (w/w). A preferred range of the amount of the Jak3 inhibitor is 0.0003% to less than 0.1% (w/w), while an even more preferred range of the amount of the Jak3 inhibitor is 0.003 to 0.03% (w/w). Another preferred range of the amount of Jak3 inhibitor is 0.005% to 0.05% (w/w), and a still more preferred range is 0.01% to 0.03% (w/w).
  • Preferably, the compositions administered according to the present invention will be formulated as solutions, suspensions, emulsions and other dosage forms for topical administration. Aqueous solutions are generally preferred, based on ease of formulation, as well as a patient's ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected eyes. However, the compositions may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions. Suspensions may be preferred for Jak3 inhibitors which are sparingly soluble in water.
  • The compositions administered according to the present invention may also include various other ingredients, including but not limited to tonicity agents, buffers, surfactants, stabilizing polymer, preservatives, co-solvents and viscosity building agents. Preferred pharmaceutical compositions of the present invention include the inhibitor with a tonicity agent and a buffer. The pharmaceutical compositions of the present invention may further optionally include a surfactant and/or a palliative agent and/or a stabilizing polymer.
  • Various tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, simple sugars such as dextrose, fructose, galactose, and/or simply polyols such as the sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, and hydrogenated starch hydrolysates may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm and most preferably at approximately 290 mOsm). In general the tonicity agents of the invention will be present in the range of 2 to 4% w/w. Preferred tonicity agents of the invention include the simple sugars or the sugar alcohols. A particular embodiment of the invention is D-mannitol.
  • An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed. Preferably however, the buffer will be chosen to maintain a target pH within the range of pH 5 to 8, and more preferably to a target pH of pH 5 to 7.
  • Surfactants may optionally be employed to deliver higher concentrations of inhibitor. The surfactants function to solubilize the inhibitor and stabilize colloid dispersion, such as micellar solution, microemulsion, emulsion and suspension. Examples of surfactants which may optionally be used include polysorbate, poloxamer, polyosyl 40 stearate, polyoxyl castor oil, tyloxapol, triton, and sorbitan monolaurate. Preferred surfactants to be employed in the invention have a hydrophile/lipophile/balance “HLB” in the range of 12.4 to 13.2 and are acceptable for ophthalmic use, such as TritonX114 and tyloxapol.
  • Compositions formulated for the treatment of dry eye-type diseases and disorders may also comprise aqueous carriers designed to provide immediate, short-term relief of dry eye-type conditions. Such carriers can be formulated as a phospholipid carrier or an artificial tears carrier, or mixtures of both. As used herein, “phospholipid carrier” and “artificial tears carrier” refer to aqueous compositions which: (i) comprise one or more phospholipids (in the case of phospholipid carriers) or other compounds, which lubricate, “wet”, approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration; (ii) are safe; and (iii) provide the appropriate delivery vehicle for the topical administration of an effective amount of one or more of the specific Jak3 inhibitors. Examples or artificial tears compositions useful as artificial tears carriers include, but are not limited to, commercial products, such as Visine Pure Tears®, Visine Tears Natural Tears Formula® (Johnson & Johnson) Tears Naturale®, Tears Naturale II®, Tears Naturale Free®, Bion Tears® (Alcon Laboratories, Inc. Forth Worth, Tex.), Refresh Tears®, Refresh Endura®, Refresh Plus® (Allergan Inc.). Examples of phospholipid carrier formulations include those disclosed in U.S. Pat. Nos. 4,804,539 (Guo et al.), 4,883,658 (Holly), 4,914,088 (glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.), 5,578,586 (Glonek et al.); the foregoing patents are incorporated herein by reference to the extent they disclose phospholipid compositions useful as phospholipid carriers of the present invention.
  • Palliative compounds designed to lubricate, “wet,” approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration of the eye are known in the art. Such palliative agents may, in some cases, serve a dual function as a tonicity agent, such as the monomeric polyols (glycerol, propylene glycol, ethylene glycol). The palliative compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, polymeric polyols, such as polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxyl propylcellulose (“HPC”), dextrans, such as dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as polyvinyl alcohol, polyvinylpyrrolidinone, povidone, and carbomers, such as, carbomer 941, carbomer 940, carbomer 971P, carbomer 974P.
  • Additional agents that may be added to the ophthalmic compositions of the present invention are demulcents which function as a stabilizing polymer. The stabilizing polymer should be an ionic/charged example with precedence for topical ocular use, more specifically a polymer that carries negative charge on it's surface that can exhibit a zeta-potential of (−)10-50 mV for physical stability and capable of making a dispersion in water (i.e. water soluble). A preferred stabilizing polymer of the invention would be polyelectrolyte or polyectrolytes if more than one, from the family of cross-linked polyacrylates, such as carbomers and Pemulen®, specifically Carbomer 974p (polyacrylic acid), at 0.1-0.5% w/w. As noted above, the carbomers may also function as a palliative compound.
  • Other compounds may also be added to the ophthalmic compositions of the present invention to increase the viscosity of the carrier. Examples of viscosity enhancing agents include, but are not limited to: polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextrans, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers. In general, the phospholipid carrier or artificial tears carrier compositions will exhibit a viscosity of 1 to 400 centipoises (“cps”).
  • Topical ophthalmic products are typically packaged in multidose form. Preservative are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edentate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically unpreserved. Such compositions, therefore, generally will not contain preservatives.
  • The preferred compositions of the present invention are intended for administration to a human patient suffering from dry eye or symptoms of dry eye. Preferably, such compositions will be administered topically. In general, the doses used for the above described purposes will bary but will be in an effective amount to eliminate or improve dry eye conditions. Generally, 1-2 drops of such compositions will be administered from once to many times per day. Preferably such compositions will be administered once (QD) or twice (BID) daily.
  • Representative eye drop formulations are provided in Example 2 below.
    • Example 1 1-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-ethanone and 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile. Method A: (1-Benzyl-4-methyl-piperidin-3-yl)-methyl-amine
  • To a stirred solution of 1-benzyl-4-methyl-piperidin-3-one (2.3 grams, 11.5 mmol), prepared by the methods of Iorio, M. A. and Damia, G., Tetrahedron, 26, 5519 (1970) and Grieco et al., Journal of the American Chemical Society, 107, 1768 (1985), (modified using 5% methanol as a co-solvent), both references are incorporated by reference in their entirety, dissolved in 23 mL of 2 M methylamine in tetrahydrofuran was added 1.4 mL (23 mmol) of acetic acid and the resulting mixture stirred in a sealed tube for 16 hours at room temperature. Triacetoxy sodium borohydride (4.9 grams, 23 mmol) was added and the new mixture stirred at room temperature in a sealed tube for 24 h, at which time, the reaction was quenched upon addition of 1 N sodium hydroxide (50 mL). The reaction mixture was then extracted 3×80 mL with ether, the combined ether layers dried over sodium sulfate (Na2SO4) and concentrated to dryness in vacuo affording 1.7 grams (69%) of the title compound as a white solid. LRMS: 219.1 (M+1).
    • Method B: (1-Benzyl-4-methyl-piperidin-3-yl)-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine
  • A solution of 4-chloropyrrolo[2,3-d]pyrimidine (2.4 grams, 15.9 mmol), prepared by the method of Davoll, J. Am. Chem. Soc., 82, 131 (1960), which is incorporated by reference in its entirety, and the product from Method A (1.7 grams, 7.95 mmol) dissolved in 2 equivalents of triethylamine was heated in a sealed tube at 100° C. for 3 days. Following cooling to room temperature and concentration under reduced pressure, the residue was purified by flash chromatography (silica; 3% methanol in dichloromethane) affording 1.3 grams (50%) of the title compound as a colorless oil. LRMS: 336.1 (M+1).
    • Method C: Methyl-(4-methyl-piperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine
  • To the product from Method B (0.7 grams, 2.19 mmol) dissolved in 15 mL of ethanol was added 1.5 mL of 2 N hydrochloric acid and the reaction mixture degassed by nitrogen purge. To the reaction mixture was then added 0.5 grams of 20% palladium hydroxide on carbon (50% water) (Aldrich) and the resulting mixture shaken (Parr-Shaker) under a 50 psi atmosphere of hydrogen at room temperature for 2 days. The Celite filtered reaction mixture was concentrated to dryness in vacuo and the residue purified by flash chromatography (silica; 5% methanol in dichoromethane) affording 0.48 grams (90%) of the title compound. LRMS: 246.1 (M+1).
    • Method D: 1-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-ethanone
  • To a stirred solution of the product from Method C (0.03 grams, 0.114 mmol) dissolved in 5 mL of 10:1 dichloromethane/pyridine was added (0.018 grams, 0.228 mmol) of acetylchloride and the resulting mixture stirred at room temperature for 18 hours. The reaction mixture was then partitioned between dichloromethane and saturated sodium bicarbonate (NaHCO3). The organic layer was washed again with saturated NaHCO3, dried over sodium sulfate and concentrated to dryness in vacuo. The residue was purified by preparative thin layer chromatography (PTLC) (silica; 4% methanol in dichloromethane) affording 0.005 mg (15%) of the title compound as a colorless oil. LRMS: 288.1 (M+1).
    • Method E: Synthesis of 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550)
  • The title compound 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550) was prepared using routine modification of the Methods A-D described above.
    • Method F: Preparation of 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate salt
  • The citrate salt was prepared using methods described in WO2007/012953. To a clean, dry, nitrogen-purged 500 ml reactor were charged methyl-4(-methyl-piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine (25.0 g, 0.102 mol) and methylene chloride (250 ml). The mixture was stirred at room temperature for a minimum of 2.5 hours. To a clean, dry, nitrogen-purged 1 L reactor were charged cyanoacetic acid (18.2 g, 0.214 mol), methylene chloride (375 ml), and triethyl amine (30.1 ml, 0.214 mol). The mixture was cooled to −15-5.0° C. over one hour and trimethylacetyl chloride (25.6 ml, 0.204 mol) was added at a rate to maintain the temperature below 0° C. The reaction was held for a minimum of 2.5 hours, then the solution of the amine was added at a rate that maintained the temperature below 0° C. After stirring for 1 hour, the mixture was warmed to room temperature and 1M sodium hydroxide (125 ml) was added. The organic layer was washed with water (125 ml). The methylene chloride solution was displaced with acetone until a volume of 500 ml and a temperature of 55-65° C. had been achieved. Water (75 ml) was charged to the mixture while maintaining the temperature at 55-65° C. A solution of citric acid (20.76 g, 0.107 mol) in water (25.0) was charged and the mixture was cooled to room temperature. The reactor was stirred for a minimum of 5 hours and then the resulting solids were isolated by filtration and washed with acetone (2×75 ml), which was sent to the filter. The salt was charged into a clean, dry, nitrogen-purged 1 L reactor with 2B ethanol (190 ml) and water (190 ml). The slurry was heated to 75-85° C. for a minimum of 4 hours. The mixture was cooled to 20-30° C. and stirred for an additional 4 hours. The solids were isolated by filtration and washed with 2B ethanol (190 ml). After drying in a vacuum oven at 50° C. with a slight nitrogen bleed, 34.6 g (67.3%) of the title compound were isolated.
  • 1H NMR (500 MHz, d6-DMSO): δ 8.14 (s, 1H, 7.11 (d, J=3.6 Hz, 1H), 6.57 (d, J=3.6 Hz, 1H), 4.96 (q, J=6.0 Hz, 1H), 4.00-3.90 (m, 2H), 3.80 (m, 2H), 3.51 (m, 1H), 3.32 (s, 3H), 2.80 (Abq, J=15.6 Hz, 2H), 2.71 (Abq, J=15.6 Hz, 2H), 2.52-2.50 (m, qH), 2.45-2.41 (m, 1H), 1.81 (m, 1H), 1.69-1.65 (m, 1H), 1.04 (d, J=6.9 Hz, 3H).
    • Method G: Preparation of free base 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile
  • The 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate salt, as prepared in Method F above, was treated with 1M sodium hydroxide in dichloromethane to afford the corresponding free base. The free base was then crystallized from methanol and water to furnish the crystal form of the free base.
    • Example 2 Pharmaceutical Formulations Example 2a Formulations
  • Table 2 below illustrates various pharmaceutical formulations comprising the inhibitor CP0690550.
  • TABLE 2
    Formulation code Formulation Description
    Formulation
    1 50 mM pH 7.4 phosphate buffer, 0.05% Tween
    80, 0.5% NaCl
    Formulation
    2 50 mM pH 7.4 Phosphate buffer, 0.36% HPMC,
    0.2% Glycerin, 1% PEG400, 0.35% NaCl
    Formulation
    3 5 mM pH 7.4 phosphate buffer, 0.36% HPMC,
    0.2% Glyerin, 1% PEG400, 5% Cremophor
    ELP, 4.3% Mannitol
    Formulation
    4 10 mM pH 5.8 citrate buffer, 4.5% Mannitol
    Formulation
    5 10 mM pH 5.8 citrate buffer, 4.2% Mannitol,
    0.36% HPMC, 0.2% Glycerin
    Formulation
    6 0.3% tyloxapol (surfactant, nonionic), 0.5%
    Carbopol974P (polymeric stabilizer, anionic),
    2.25% D-mannitol, pH 6.5 phosphate buffer at
    50 mM concentration, 230 mOsm/kg
    Formulation
    7 0.3% tyloxapol (surfactant, nonionic), 0.1%
    Carbopol974P (polymeric stabilizer, anionic),
    2.25% D-mannitol, pH 6.5 phosphate buffer at
    50 mM concentration, 230 mOsm/kg
    • Example 2b Preparation
  • Each of the above formulations 1 through 5 were prepared comprising the Jak3 inhibitor CP0690550 in three dosage amounts: 0.001%, 0.003% and 0.01% w/w. Formulation 5 was also prepared with the Jak3 inhibitor CP9690550 in the amount of 0.005% w/w (see FIG. 8). Formulations 6 and 7 were prepared comprising Jak3 inhibitor in the amount of 0.03% w/w.
  • The above formulations were prepared by adding the required amount of the tonicity agent (hypromellose, or mannitol where present) to a flask, heating to about to about 50° C. in half the final volume of buffer (phosphate or citrate buffer as indicated). After heating the batch quantities of inhibitor CP690550, the additional excipients (glycerin, polyethylene glycol 400, where indicated) were weighed and dissolved. The batch quantity of the Jak3 inhibitor free base as a stock solution was measured and added. Purified water was added to q.s. to 100%. The mixture was stirred for five minutes to homogenize and then filtered through a sterilizing filter membrane into a sterile recipient. If necessary, pH was adjusted by admixture of 1.0 NaOH.
  • Formulations 6 and 7 represent ophthalmic compositions in which higher amounts of the inhibitor CP690550 are present (0.03% w/w). In addition to a tonicity agent and buffer, such higher concentrate formulations will also include a surfactant and optionally a stabilizing polymer. Preferred surfactants of the invention include TritonX114 and tyloxapol. Preferred stabilizing polymers include the carbomer 974p.
  • Preparation of Formulations 6 and 7 were prepared by dispersing the carbomer first in the surfactant containing buffer at 10× of their final concentration (e.g. 3% tyloxapol in 50 mM phosphate buffer at pH6.5 with 2.5% D-manitol and 5% Carbomer 974p). The Jak3 inhibitor CP690550 was dispersed in the preconcentrate also at 10× of its final concentration. The mixture was then homogenized, with final formulation being obtained by 10× dilution of filtered preconcentrate in a matching buffer.
    • Example 3 Effect of selective Jak3 inhibitor on Tear Production MRL/Ipr (Dry Eye) Mice
  • To study the level of tear production over time, 10 MRL/Ipr mice and 5 of the age-matched C57 Black/6 control mice at 8 weeks of age were purchased from Jackson Laboratory (Bar Harbor, Me., USA). The mouse strain MRL/Ipr has a mutation which predisposes it to dry eye similar to Sjogren's Syndrome.
  • Baseline tear volume was established by measuring of tear volume 4 times over one week to establish that dry eye occurred in MRL/Ipr mice versus C57 mice. Tear production was measured with cotton thread (Quick Zone®) held with forceps and applied to the ocular surface at the lateral canthus for 15 to 30 seconds. Wetting of the thread was measured in millimeters. Tear production measurements of MRL/Ipr mice versus C57control mice are shown in FIG. 1.
  • Animals (5-10 mice/group) were treated with 2 μl of either vehicle (phosphate buffered saline, PBS, containing 0.05% Tween 80) or 0.1% (w/w) CP-690550 twice a day for two weeks. C57 mice also received vehicle. Tear volume was measured on days 2, 3, and 6. The effect of CP-690550 on tear production in MRL/Ipr Mice is shown in FIG. 2.
  • As shown in FIG. 2, CP0690550 was able to significantly increase tear production volume within the first 2 days of application. Notably, CP690550 increased tear production volume by over 100% over initial tear production of the dry eye mice within the first 2 days of application.
    • Example 4 Comparative data comparing CP-690550 to Restasis®
  • Tear measurement was done using phenol red impregnated thread (Quick Zone®) and baseline measurement was performed before each drug application. Drugs or vehicles were applied at 2 μl, two times a day.
  • Vehicle-treated normal C57black/6 and MRL/Ipr dry eye mice were used as normal control and dry eye control, respectively. The vehicle for CP690550 was phosphate buffered saline, PBS, containing 0.05% Tween 80.
  • The experiment to compare efficacy of CP690550 and Restasis® was done using Restasis® (cyclosporine 0.05%) and CP-690550 at 0.01% applied twice a day for 30 days. Control animals included normal C57Black/6 mice, and MRL/Ipr mice, treated with PBS vehicle and MRL/Ipr mice treated with Refresh Endura® (vehicle for Restasis) (5-10 mice/group). Comparative tear production of CP-690550 and Restasis® is shown in FIG. 3.
  • As shown in FIG. 3, CP690550 had a much faster response rate as compared to Restasis® and showed a significant improvement in the volume of tear production over Restasis®
  • Moreover, both FIGS. 3 and 4 indicate that administration of CP690550 ultimately increased tear production volume to a level comparable to that of normal tear production (within 5 to 10% of tear production by “normal” C57mice).
    • Example 5 Dose response Rates of CP690550 in MRL/Ipr Mice
  • As with Example 4 above, vehicle-treated normal C57black/6 and MRL/Ipr dry eye mice (5-10 mice/group) were used as normal control and dry eye control, respectively. The vehicles for CP690550 were Formulations 1, 3 and 4 as indicated in Example 2 above. The Jak3 inhibitor CP690550 was applied at 0.003% (w/w), 01% (w/w) and 0.03% (w/w), as calculated for free base concentration. Treatment for Formulation 1 was carried for two weeks, at 41, twice a day. Treatment for Formulations 3 and 4 were carried for 2 weeks, at 1 μl, once a day.
  • FIG. 4 illustrates that within 8 days, administration of CP690550 in Formulation 1 vehicle at 0.01% (w/w) twice a day increased tear production to a level comparable to that of normal tear production (within 5 to 10% of tear production by C57 normal mice). Similarly, FIGS. 5 and 6 illustrate dose response rates of CP690550 in Formulations 3 and 4 vehicle. In all comparisons, significant improvement in tear production was shown at 2 days after treatment.
    • Example 6 Induced Dry Eye Mouse Model
  • An injection was prepared comprising 2.5 mg/ml scopolamine (sigma) in injectable saline (1-1.5 ml per animal). In normal C57 mice (200-250) ul of scopolamine was injected four times every 2.5 hrs in alternating hind quarters. The mice were placed in special cages (with holes in front and back) and placed in a hood. Fans were placed in front of each cage, and turned on for 16 hours over night for five days. Measurements were taken daily. At the end of 5 days, all animals were considered dry-induced.
  • As with Examples 4 and 5 above, animals were treated with drug or vehicle at 1 μl, once a day for 2 weeks. Vehicle-treated C57 black/6 and the dry-induced mice (5-10 mice/group) were treated with Formulations 3 and 5 as prepared in Example 2 above. FIGS. 7 and 8 illustrate that a significant increase in tear production was shown at 2 days of treatment. After 4 days of treatment, formulations comprising 0.01% (w/w) of CP0690550 inhibitor in Formulation 3 and 0.003% of CP690550 inhibitor in Formulation 5 approximated normal tear production values.
  • This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims (15)

What is claimed is:
1. A topical ophthalmic composition comprising a pharmaceutically effective amount of a Jak3 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
2. The topical ophthalmic composition of claim 1, wherein the Jak3 inhibitor is 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550), and has the structure:
Figure US20130303557A1-20131114-C00005
3. The ophthalmic composition of claim 2, wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.0001 to less than 0.1% (w/w).
4. The ophthalmic composition of claim 1, wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.003 to 0.03% (w/w).
5. The ophthalmic composition of claim 1, wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.01 to 0.03% (w/w).
6. The ophthalmic composition of claim 2, wherein the buffer maintains a target pH within the range of pH 5 to 8.
7. The ophthalmic composition of claim 2, further comprising a tonicity agent and a buffer selected from phosphate or citrate.
8. The ophthalmic composition according to claim 7, further comprising a surfactant.
9. The ophthalmic composition according to claim 8, wherein the surfactant is tyloxapol.
10. A topical ophthalmic composition comprising a pharmaceutically effective amount of the Jak3 inhibitor 3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile (CP0690550), or a pharmaceutically acceptable salt thereof:
Figure US20130303557A1-20131114-C00006
and a pharmaceutically acceptable carrier.
11. The ophthalmic composition of claim 10, wherein the pharmaceutically effective amount of Jak3 inhibitor is 0.0001 to less than 0.1% (w/w).
12. The ophthalmic composition of claim 10, wherein the pharmaceutically effective amount of Jak3 inhibitor is about 0.03% (w/w).
13. The ophthalmic composition of claim 11, wherein the buffer maintains a target pH within the range of pH 5 to 8.
14. The ophthalmic composition of claim 13, further comprising a tonicity agent and a buffer selected from phosphate or citrate, and a surfactant.
15. The ophthalmic composition according to claim 14, wherein the surfactant is tyloxapol.
US13/944,816 2007-07-11 2013-07-17 Pharmaceutical compositions and methods of treating dry eye disorders Abandoned US20130303557A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/944,816 US20130303557A1 (en) 2007-07-11 2013-07-17 Pharmaceutical compositions and methods of treating dry eye disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94921607P 2007-07-11 2007-07-11
US6003208P 2008-06-09 2008-06-09
US12/668,604 US8541426B2 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders
PCT/IB2008/001819 WO2009007839A1 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders
US13/944,816 US20130303557A1 (en) 2007-07-11 2013-07-17 Pharmaceutical compositions and methods of treating dry eye disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/688,604 Division US8509688B2 (en) 2009-04-23 2010-01-15 Apparatus and method for mac logical channel selection for operating piconets in body area networks

Publications (1)

Publication Number Publication Date
US20130303557A1 true US20130303557A1 (en) 2013-11-14

Family

ID=39925011

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/668,604 Expired - Fee Related US8541426B2 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders
US13/944,816 Abandoned US20130303557A1 (en) 2007-07-11 2013-07-17 Pharmaceutical compositions and methods of treating dry eye disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/668,604 Expired - Fee Related US8541426B2 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders

Country Status (15)

Country Link
US (2) US8541426B2 (en)
EP (1) EP2175858B1 (en)
JP (2) JP5649270B2 (en)
KR (2) KR101258316B1 (en)
CN (1) CN101743009A (en)
AR (1) AR067495A1 (en)
AU (1) AU2008273804B2 (en)
BR (1) BRPI0813553A2 (en)
CA (1) CA2691914C (en)
ES (1) ES2523303T3 (en)
NZ (1) NZ582188A (en)
RU (1) RU2445098C2 (en)
TW (1) TWI364281B (en)
WO (1) WO2009007839A1 (en)
ZA (1) ZA201000991B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104857287A (en) * 2015-04-21 2015-08-26 湖南中医药大学 Traditional Chinese medicine eye-drop for treating xeroma and preparation method thereof
WO2018017479A1 (en) * 2016-07-18 2018-01-25 Regentree, Llc Methods of treating dry eye syndrome

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR101312225B1 (en) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Compositions and methods for inhibition of the jak pathway
UA116187C2 (en) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн HETERO aryl substituted pyrrolo [2,3-b] Pyridines and pyrrolo [2,3-b] Pyrimidines as Janus kinase inhibitors
ES2714092T3 (en) 2007-06-13 2019-05-27 Incyte Holdings Corp Use of Janus (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanonitrile kinase inhibitor salts
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CL2009001884A1 (en) * 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
CN102459270B (en) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Piperidine inhibitors of janus kinase 3
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
UA106078C2 (en) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptanenitrile as jak inhibitors
CN102470135A (en) * 2009-07-28 2012-05-23 里格尔药品股份有限公司 Compositions and methods for inhibition of the JAK pathway
TWI643857B (en) 2010-03-10 2018-12-11 英塞特公司 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (en) 2010-05-21 2013-02-27 Incyte Corp TOPICAL FORMULATION FOR A JAK INHIBITOR
JP5917545B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AU2012241018B2 (en) * 2011-04-08 2015-11-12 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
AR086983A1 (en) 2011-06-20 2014-02-05 Incyte Corp DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
NZ748448A (en) 2012-11-15 2019-12-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103073552B (en) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 A kind of unformed Citric Acid holder method is for the preparation method of Buddhist nun
TWI634121B (en) 2013-03-06 2018-09-01 英塞特控股公司 Processes and intermediates for making a jak inhibitor
CN104341422A (en) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 Tofacitinib intermediate and preparation method thereof
KR20220103810A (en) 2013-08-07 2022-07-22 인사이트 코포레이션 Sustained release dosage forms for a jak1 inhibitor
CN104447752A (en) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 Tofacitinib hydrate and preparation method thereof
CN104447751A (en) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 Tofacitinib compound
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
AU2015336396B2 (en) * 2014-10-22 2020-12-10 HLB Therapeutics Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
AU2019213665B2 (en) 2018-01-30 2024-06-13 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
EP3746086A4 (en) 2018-01-31 2021-10-20 TWI Biotechnology, Inc. Topical formulations comprising tofacitinib
SI3773593T1 (en) 2018-03-30 2024-08-30 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US20220280515A1 (en) * 2019-08-07 2022-09-08 Rohto Pharmaceutical Co., Ltd. Ophthalmic Composition for Promoting Tear Secretion
US20230101139A1 (en) * 2019-12-27 2023-03-30 Rohto Pharmaceutical Co., Ltd. Aqueous Composition
TW202135822A (en) * 2019-12-27 2021-10-01 日商樂敦製藥股份有限公司 Aqueous composition
CN111467349B (en) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 Artificial tear and preparation method thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN114948991A (en) * 2021-02-26 2022-08-30 复旦大学 Application of magnesium hydride in preparation of medicine for preventing and treating ocular surface inflammation related to xerophthalmia
TW202329961A (en) * 2021-11-30 2023-08-01 日商興和股份有限公司 Novel nicotinamide compound and use therefor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
WO2000056338A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
EA006227B1 (en) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS
US20020132767A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
AR035293A1 (en) * 2001-08-23 2004-05-05 Novartis Ag OPHTHALMIC COMPOSITION.
GT200200234A (en) 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
RU2285511C2 (en) * 2004-10-13 2006-10-20 НИИ ГБ им. Гельмгольца Means for treating the cases of dry eye syndrome
RU2290923C2 (en) * 2005-03-04 2007-01-10 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Method for treating the cases of dry eye syndrome
EP1874772A1 (en) * 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) * 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
SI1913000T1 (en) 2005-07-29 2012-02-29 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en) * 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
JP2007314326A (en) * 2006-05-26 2007-12-06 Mitsubishi Heavy Ind Ltd Chopper folding method and device
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104857287A (en) * 2015-04-21 2015-08-26 湖南中医药大学 Traditional Chinese medicine eye-drop for treating xeroma and preparation method thereof
CN104857287B (en) * 2015-04-21 2021-05-11 湖南中医药大学 Traditional Chinese medicine eye drops for treating xerophthalmia and preparation method thereof
WO2018017479A1 (en) * 2016-07-18 2018-01-25 Regentree, Llc Methods of treating dry eye syndrome
EP3484497A4 (en) * 2016-07-18 2020-01-01 Regentree, LLC Methods of treating dry eye syndrome
US10960051B2 (en) 2016-07-18 2021-03-30 Regentree, Llc Methods of treating dry eye syndrome

Also Published As

Publication number Publication date
BRPI0813553A2 (en) 2017-05-09
RU2009149687A (en) 2011-07-10
ES2523303T3 (en) 2014-11-24
RU2445098C2 (en) 2012-03-20
EP2175858B1 (en) 2014-09-10
US8541426B2 (en) 2013-09-24
US20100267751A1 (en) 2010-10-21
CN101743009A (en) 2010-06-16
ZA201000991B (en) 2010-12-29
EP2175858A1 (en) 2010-04-21
KR20120115413A (en) 2012-10-17
JP2009046470A (en) 2009-03-05
AU2008273804A1 (en) 2009-01-15
CA2691914C (en) 2012-06-26
AU2008273804B2 (en) 2014-07-10
KR101258316B1 (en) 2013-04-30
TW200911265A (en) 2009-03-16
NZ582188A (en) 2012-03-30
JP5649270B2 (en) 2015-01-07
JP2013147517A (en) 2013-08-01
WO2009007839A1 (en) 2009-01-15
AR067495A1 (en) 2009-10-14
TWI364281B (en) 2012-05-21
CA2691914A1 (en) 2009-01-15
KR20100029823A (en) 2010-03-17

Similar Documents

Publication Publication Date Title
US8541426B2 (en) Pharmaceutical compositions and methods of treating dry eye disorders
AU2005229006B9 (en) Use of loteprednol etabonate for the treatment of dry eye
KR101786760B1 (en) Anionic oil-in-water emulsions containing prostaglandins and uses thereof
JP7465453B2 (en) Preparation of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
EP2823814A1 (en) Pharmaceutical composition for use in medical and veterinary ophthalmology
JP2024129025A (en) Ophthalmic compositions of rifamycin and uses thereof
ES2334368T3 (en) PROCESS OF TREATMENT OF DRY EYE DISORDERS AND UVEITIS.
KR101813211B1 (en) Cationic oil-in-water emulsions containing prostaglandins and uses thereof
WO2018056269A1 (en) Eye drops containing jak inhibitor
JP2005047909A (en) Remedy for pruritus containing piperidine derivative as active ingredient
JP2023536938A (en) Crystal forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
Taylor et al. Dry eyes in rheumatic disease
JP7118579B1 (en) Aqueous composition containing epinastine or its salt
JP2018048133A (en) Agent for the treatment and/or prevention of inflammatory eye disease

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION